AU
UK
CA
NZ
IND
US
On Tuesday,Morgan Stanley (NYSE:MS)upgradedKymera Therapeutics (NASDAQ:KYMR)fromEqualweighttoOverweight, raising its price target toUSD79fromUSD49. The move reflects growing interest in the clinical progress of Kymera's drug pipeline, particularly its STAT6-targeting therapy KT-621.
The Ensign Group, Inc. (Nasdaq: ENSG) announced the acquisition of operations at three skilled nursing facilities, adding 232 licensed beds to its portfolio. The acquisitions include Ironwood Rehabilitation and Care Center (80 beds) and Lakeside Rehabilitation and Care Center (100 beds), both located in …
Personalis, Inc. (Nasdaq: PSNL) announced new clinical data from the PREDICT DNA and SCANDARE studies at the ASCO 2025 Annual Meeting, presenting findings that suggest its NeXT Personal™ ctDNA test could serve as a significant prognostic tool for patients with triple negative breast cancer …
Piper Sandler upgraded Claritev Corporation (NYSE: CTEV) toOverweight from Neutralfollowing the company’s Q1 2025 financial results and strategic developments. The firm also increased its price target substantially, from USD 19 to USD 44, reflecting revised expectations for Claritev’s future performance.
InflaRx N.V. (Nasdaq: IFRX) announced that its Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) will be discontinued following a recommendation from the Independent Data Monitoring Committee (IDMC). The IDMC concluded that continuing the trial would be futile based on an unblinded interim …
BioSig Technologies, Inc. (Nasdaq: BSGM) has signed a definitive share exchange agreement with Streamex Exchange Corporation, a private company focused on tokenizing real-world assets, particularly commodities. The agreement will result in Streamex becoming a wholly owned subsidiary of BioSig through an exchange of Streamex …
Moderna, Inc. (NASDAQ: MRNA) has submitted an application to the U.S. Food and Drug Administration (FDA) seeking review and authorization for its updated COVID-19 vaccine formula, Spikevax 2025-2026. The new formulation is designed specifically to target the SARS-CoV-2 variant LP.8.1.
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, has entered into definitive agreements for a private placement involving the issuance and sale of 7,222,223 shares of its common stock—or pre-funded warrants in lieu thereof—along with short-term warrants to purchase up to 14,444,446 shares of …
Invivyd, Inc. (Nasdaq: IVVD) announced that its monoclonal antibody PEMGARDA® (pemivibart) has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas. The update identifies PEMGARDA as a potential pre-exposure prophylaxis (PrEP) option against COVID-19 for patients …
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) presented new long-term data from its Phase 2 TELLOMAK trial evaluating lacutamab in Sézary syndrome (SS) and mycosis fungoides (MF) at the ASCO 2025 Annual Meeting. The findings, as of the October 17, 2024 data cut-off, …
Please wait processing your request...